Investigation on possible down-regulation of adverse effects of SARS-CoV-2 vaccination by type 2 allergic diseases using questionnaire to vaccine recipients
Not Applicable
- Conditions
- vaccine adverse effects
- Registration Number
- JPRN-UMIN000044489
- Lead Sponsor
- Allergic Disease Research Center, Chutoen General Medical Center
- Brief Summary
For the systemic reactions, fatigability after the first dose tended to be more severe in the bronchial asthma than in the non-allergic group. Headache, joint pain, and fever tended to be more severe in the food allergy than in the non-allergic group after the second dose. For the local skin reactions, atopic dermatitis subjects tended to show rather less severe local skin reactions after the second dose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 955
Inclusion Criteria
Not provided
Exclusion Criteria
Apparent loss or mistake in the questionnaire sheet.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of differences in vaccine adverse effects (injection reactions [pain, swelling, and erythema], fever, headache, fatigability, muscle pain, joint pain, and others) between recipients who have present and past allergic diseases (atopic dermatitis, allergic rhinitis, bronchial asthma, and others) and those without these allergic diseases.
- Secondary Outcome Measures
Name Time Method Evaluation of differences in the severity of vaccine adverse effects between recipients who have present and past allergic diseases (atopic dermatitis, allergic rhinitis, and bronchial asthma) and those without these allergic diseases.